Madison, WI—ConjuGon, Inc. will receive $2.4 million in federal funds to help continue development of its novel wound infection treatment product. ConjuGon’s work has life-saving promise for both military and public health care. The funds, requested by Congresswoman Tammy Baldwin (D-WI), were included in the Department of Defense Appropriations Bill for Fiscal Year 2009 which was signed into law on September 30th. Rep. Baldwin secured $1.2 million for the same project in Fiscal Year 2008.
“We are very excited to receive this federal funding. Military personnel and civilians often develop life-threatening bacterial infections following traumatic injury, and current antibiotics to fight these infections are becoming much less effective. Our aim is to deliver this novel antibacterial product to those in need as soon as possible, and these funds will help us reach that goal” said ConjuGon’s COO Steve Watt. “We would like to thank Congresswoman Baldwin for securing these funds, which support high-tech businesses and job creation in Wisconsin.”
“I’m delighted to help bring federal funds and national attention home to Wisconsin for this ground-breaking medical research. This kind of federal/local partnership creates good jobs along with revolutionary treatments that will save many, many lives,” said Rep. Baldwin.
ConjuGon is developing fundamentally new technologies to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon has two novel, biological products - one to prevent Catheter Associated Urinary Tract Infections and a second to treat antibiotic resistant wound infections. The company is located in the University Research Park in Madison, WI.